Mural Oncology's Upcoming Presentations at SITC
Mural Oncology plc (NASDAQ: MURA), a prominent player in clinical-stage immunotherapy, is excited to announce its participation in the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) where groundbreaking advancements in their research will be showcased. This prestigious annual event will be held in Houston from November 6-10.
The company is poised to unveil critical findings from its phase 1/2 ARTISTRY-3 study, which explores the pharmacodynamics involved in administering nemvaleukin, Mural's uniquely engineered interleukin-2 (IL-2), at less frequent intervals. The presentation also includes compelling data consolidating their two preclinical programs targeting IL-18 and IL-12.
Poster Presentation Details
Mural Oncology's poster presentations will provide in-depth insights and findings in three distinct areas:
- Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8 - Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9 - Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9
Innovative Approach to Immunotherapy
Mural Oncology is revolutionizing cancer treatment through its innovative protein engineering platform, which focuses on combining the nuances of cytokine biology with cutting-edge immune modulation. This approach is designed to not only enhance the efficacy but also to minimize adverse effects often associated with traditional immunotherapies.
The cornerstone of their research is nemvaleukin, which is currently being tested in potentially registrational trials among patients with platinum-resistant ovarian cancer and mucosal melanoma, with peak data expected in the near term.
The Potential of IL-18
The IL-18 program at Mural Oncology represents a significant leap forward. While IL-18 is a potent immune-activating cytokine, its effectiveness has previously been limited by the presence of IL-18 binding protein (IL-18BP). By utilizing a novel engineering approach, Mural has developed variants of IL-18 that do not bind to IL-18BP, therefore bolstering its availability and action in the body.
This new formulation also involves attaching scaffolds to IL-18, effectively extending its half-life in circulation. The company aims to nominate a development candidate for the IL-18 program soon and is looking forward to filing an Investigational New Drug (IND) submission by the end of 2025.
Pioneering the IL-12 Pathway
Similarly, Mural is forging new paths with its approach to IL-12, a cytokine recognized for its strong pro-inflammatory properties, albeit with considerable toxicity. To lessen this risk, Mural Oncology has innovatively split the IL-12p70 heterodimer into inactive forms that are separately combined with antibody fragments. This allows for a precise delivery to tumor sites while avoiding systemic exposure.
Preclinical results suggest that this strategy helps sustain therapeutic concentrations within tumors while minimizing side effects. The objective is to have a capable candidate for the IL-12 program named by year's end.
Commitment to Advancing Cancer Treatment
Mural Oncology's mission is underscored by a commitment to redefine the landscape of cancer treatment through innovative approaches that not only eliminate tumor cells but also enhance the quality of life for patients. By continually evolving their programs and maintaining a focus on scientific advancement, the company is poised to make significant contributions to the field of immuno-oncology.
Frequently Asked Questions
What is Mural Oncology focused on presenting at SITC?
Mural Oncology will present data regarding nemvaleukin dosing and findings from preclinical research programs on IL-18 and IL-12.
Where will the SITC meeting take place?
The SITC Annual Meeting will be hosted in Houston, Texas.
What is nemvaleukin?
Nemvaleukin is an engineered cytokine designed to improve the therapeutic effects of IL-2 while minimizing associated toxicities.
How does Mural Oncology enhance the effectiveness of IL-18?
Mural's engineering efforts focus on avoiding IL-18BP binding and extending IL-18's half-life for enhanced therapeutic potential.
What advantages does Mural's approach to IL-12 offer?
By splitting IL-12 into inactive units and targeting tumors directly, Mural aims to significantly reduce systemic toxicity while maintaining tumor efficacy.
